Population pharmacokinetics of mycophenolic acid in pediatric renal transplant patients using parametric and nonparametric approaches. by Prémaud, Aurélie et al.
Population pharmacokinetics of mycophenolic acid in
pediatric renal transplant patients using parametric and
nonparametric approaches.
Aure´lie Pre´maud, Lt Weber, B. To¨nshoff, V. W Armstrong, M. Oellerich, S.
Urien, Pierre Marquet, Annick Rousseau
To cite this version:
Aure´lie Pre´maud, Lt Weber, B. To¨nshoff, V. W Armstrong, M. Oellerich, et al.. Population
pharmacokinetics of mycophenolic acid in pediatric renal transplant patients using parametric
and nonparametric approaches.. Pharmacological Research, Elsevier, 2011, 63 (3), pp.216-224.
<10.1016/j.phrs.2010.10.017>. <inserm-00541907>
HAL Id: inserm-00541907
http://www.hal.inserm.fr/inserm-00541907
Submitted on 30 Mar 2012
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.

1 
 
Population pharmacokinetics of mycophenolic acid in pediatric renal 
transplant patients using parametric and nonparametric approaches 
  
 A Prémaud 
1,2
, LT Weber 
3
, B Tönshoff 
4
, V W Armstrong 
5
, M Oellerich 
5
, S Urien 
6
, P Marquet 
1,2,7
, A Rousseau 
1,8
 
 
1
INSERM U850, Limoges, France 
2
Univ Limoges, Faculty of Medicine, Laboratory of Clinical Pharmacology, Limoges, France 
3
Pediatric Nephrology, University Children‟s Hospital, Ludwig-Maximilian‟s-University, Munich, 
Germany 
4
University Children‟s Hospital, 69120 Heidelberg, Germany 
5
Department of Clinical Chemistry, University Medical Center of Göttingen, Germany 
6
CIC-0901 – INSERM & EA-3620 - Université Paris Descartes, France 
7 
CHU Limoges, Department of Pharmacology and Toxicology, Limoges, France  
8
Univ Limoges, Faculty of Pharmacy, Department of Biomathematics, Limoges, France 
Corresponding author:  
Dr. Annick Rousseau, 
 
INSERM U850, Laboratory of Clinical Pharmacology 
 Faculty of Medicine, Limoges University 
 
2 rue du Dr. Marcland 
 
87025 Limoges cedex France 
 
Tél. +33 555 43 58 46  Fax. +33 555 43 59 36  E-mail: annick.rousseau@unilim.fr 
2 
 
ABSTRACT 
Mycophenolic acid (MPA) is an immunosuppressive drug widely used in the prevention of acute 
rejection in pediatric renal transplant recipients and is characterized by a wide inter-individual 
variability in its pharmacokinetics. The aim of this study was to compare population pharmacokinetic 
modeling of MPA in pediatric renal transplant recipients given mycophenolate mofetil, the ester 
prodrug of MPA, using parametric and nonparametric population methods. The data from 34 pediatric 
renal transplants (73 full pharmacokinetic profiles obtained on day 21, months 3, 6 and 9 post-
transplant) were analyzed using both the nonlinear mixed-effect modeling (NONMEM) and 
nonparametric adaptive grid (NPAG) approaches, based on a two-compartment model with first order 
lagged time absorption and first order elimination.  The predictive performance of the two models was 
evaluated in a separate group of 32 patients. Higher mean population parameter values and ranges of 
individual pharmacokinetic parameters were obtained with NPAG, especially for the elimination 
constant ke: mean 1.16 h
-1 
(0.26 to 4.33 h
-1
) and 0.78 h
-1
 (0.66 to 1.15 h
-1
) with NPAG and NONMEM, 
respectively. With NPAG, the skewness and kurtosis values for ke (2.03 and 7.80, respectively) were 
far from the theoretical values expected for normal distributions. Such a non-normal distribution could 
explain the high value of shrinkage (35%) obtained for this parameter with the parametric NONMEM 
method. Bayesian forecasting of mycophenolic acid exposure using the NPAG population 
pharmacokinetic parameters as priors yielded a better predictive performance, with a significantly 
smaller bias than with the NONMEM model (-1.68% vs -9.53%, p<0.0001). In conclusion, in the 
present study, NPAG was found to be the most adequate population pharmacokinetic method to 
describe the pharmacokinetics of MPA in pediatric renal transplant recipients.  
 
Keywords: mycophenolic acid, pediatric, renal transplantation, population pharmacokinetics, 
parametric, nonparametric. 
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1. INTRODUCTION 
Mycophenolate mofetil (MMF), the ester prodrug of mycophenolic acid (MPA) has been approved for 
immunosuppressive therapy in combination with calcineurin inhibitors following renal transplantation, 
both in adults and children. MMF, which is dosed based on body surface area in the pediatric 
population, was shown to be effective in the prevention of acute rejection in pediatric renal transplant 
recipients, and is now widely used for maintenance immunosuppressive therapy in this population [1-
4]. 
As in adults, the pharmacokinetics (PK) of MPA in pediatric renal transplant recipients is characterized 
by a large inter- and intra-individual variability, particularly in the early post-transplant period [5,6]. This 
variability is clinically relevant as shown by the association between the risk of acute rejection 
episodes and MPA AUC0-12h values [5,7]. The pharmacokinetics of MPA is also characterized by a 
large inter-individual variability and a gradual increase in dose-normalized exposure over time in the 
first three months post-transplantation [6,8]. In a population analysis based on a two-compartment 
model with time-lagged first order absorption, van Hest et al [9] found that this time dependency could 
be due to a combination of improving creatinine clearance, progressively increasing albumin, 
hemoglobin and decreasing cyclosporine predose concentrations (C0) during the first 6 months after 
transplantation. 
A decreased incidence of acute rejection has been found as a result of therapeutic drug monitoring 
(TDM) of MPA in adult [10] renal allograft recipients, and suggested in pediatric [11] recipients. 
However, establishing such a strategy requires characterization and modeling of MPA 
pharmacokinetics in the target population. Sophisticated pharmacokinetic models able to describe the 
complex plasma concentration profiles observed in adult allograft recipients in the early post-
transplantation period [12], or the enterohepatic recirculation often observed when MMF is combined 
with tacrolimus [13-16] or sirolimus [17], have been reported.  
Some authors have proposed algorithms based on a limited number of sampling time points, able to 
predict MPA inter-dose area under the curve (AUC0-12h) in pediatric kidney graft recipients on MMF 
and cyclosporine therapy [18-20]. Bayesian forecasting methods based on population PK models 
represent an alternative approach to predict the individual MPA PK parameters, hence concentration 
profiles. Using Bayesian estimators developed in populations of adult renal transplants at early and 
late post-transplantation periods, and based on a limited strategy of three time points (20min, 1h and 
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3h post-dose) [21], the APOMYGRE trial showed the feasibility, efficacy, safety and cost-effectiveness 
of MMF dose individualization in adult renal transplant patients using such Bayesian estimators 
[10,22,23]. However, these Bayesian estimators were developed using the iterative two-stage 
Bayesian method and an in-house computer program. A more common approach is one-stage 
population pharmacokinetic modeling. Payen et al. [24] reported a population pharmacokinetic 
analysis of MPA in pediatric and also adolescent renal transplant patients performed using NONMEM 
(NONlinear Mixed-Effect Modeling software), and the development of a Bayesian estimator based on 
this population model to predict MPA exposure. Most of the pharmacokinetic profiles were collected in 
stable patients as more than half of the patients were grafted for more than six months.  
To the best of our knowledge, the published one-stage population pharmacokinetic analyses of MPA 
were based on a parametric approach, mostly using NONMEM  [13, 15, 24- 29]. Usually, following 
such a parametric approach the influence of covariates on the PK parameters is analyzed and the 
remaining, unexplained inter-individual variability of the PK parameters is assumed to follow a 
predefined distribution e.g. a normal or log-normal distribution. However, when such a parametric 
approach is inappropriate to describe the unexplained inter-individual variability, implementation of 
Box-Cox or Logit transformations in NONMEM have been recently proposed [30]. These methods 
have been called “semi-parametric” as the shape of the transformed distribution is no more Gaussian. 
Non-parametric methods can describe the actual distribution of random effects whatever its shape [31-
33]. These methods are able to directly discover, in the population itself, unsuspected subpopulations 
of individuals (i.e., without external help such as descriptors, covariates or individual Bayesian 
posterior parameter estimates), which is not possible with parametric techniques. Non-parametric 
methods also provide the traditional estimates of the parameter: mean, standard deviation, mode, 
median, correlation and covariance. 
The aim of this study was to characterize MPA PK in pediatric renal transplant patients using several 
population approaches, namely nonlinear mixed-effect modeling (NONMEM) with or without semi-
parametric transformations of the inter-individual variability, and the nonparametric adaptive grid 
(NPAG) method. 
 
2. MATERIAL AND METHODS 
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2.1. Patients 
The population analysis was performed using pharmacokinetic data issued from two different cohorts 
of pediatric renal transplant recipients on a comparable immunosuppressive regimen consisting of 
mycophenolate mofetil (600 mg/m² body surface area twice a day, up to a maximum of 2g/day), 
cyclosporine and corticosteroids. The two patient cohorts have been described in detail in a previous 
paper [18]. 44 patients (28 boys) of the Cohort of the German Study group on MMF therapy, with a 
median age of 10.7 years (range, 3.2 to 15.9) and 22 patients (14 boys) of the Tricontinental MMF 
suspension trial, with a median age of 7 years (range, 1 to 16) were analyzed. The parents of the 
patients gave informed consent for the participation of their children and the clinical trial were designed 
in accordance with legal requirements. One to three profiles were collected in each patient, so that the 
66 pediatric patients provided 129 full pharmacokinetic profiles (of 9 blood samples collected at: 
predose, 20 min, 40 min, 75 min, 2, 4, 6, 8 and 12h after dosing; or of 8 blood samples collected at: 
predose, 30 min 1, 1.5, 2, 4, 8 and 12h after dosing) on day 21 and months 3, 6, and 9 post-
transplant.  
The whole dataset was randomly divided into 2 groups: a reference group made of 34 patients (73 
pharmacokinetic profiles) was used to develop the population pharmacokinetic models and a test 
group of the remaining 32 patients (56 pharmacokinetic profiles) was used to evaluate the predictive 
performance of the population models.  
 
2.2. MPA analysis 
MPA plasma concentrations were measured using a reverse-phase high-performance liquid 
chromatography method with ultraviolet detection previously described in details [34]. The error 
pattern of the assay was determined by measuring several assay samples (which cover the full 
working range of the assay) in at least quadruplicate leading to find standard deviation (SD) for each 
of the samples. Then, the overall relationship between the plasma concentration and the SD with 
which it has been measured was expressed by the following polynomial equation:   
SD = 0.963 + 0.0227C+ 0.008C²,  
where SD is the assay standard deviation and C is the measured plasma concentration. 
 
2.3. Pharmacokinetic population modeling 
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The plasma concentration versus time data of the index group were analyzed using two population 
pharmacokinetic approaches in parallel: NONMEM and nonparametric adaptive grid (NPAG) methods. 
 
2.3.1.  NONMEM analysis 
Data were analyzed using NONMEM version VI [35] and Wings for NONMEM® version 614 (N. 
Holford, Auckland, New Zealand). All population pharmacokinetic analyses were performed using the 
first order conditional estimation (FOCE) method with interaction. 
A two-compartment model with first-order, lagged time absorption and first-order elimination best 
described the data.  
Unexplained inter-individual variability (IIV) was initially modeled following an exponential error model. 
The semi-parametric approach proposed by Petersson et al. [30] was also tested:  two transformations 
with estimated shape parameter (Box-cox and logit) were explored to evaluate if they could improve 
data fitting.  
Inter-occasion variability (IOV) was modeled using an exponential error model. Diagonal matrix and 
full variance/covariance matrix (using the Block() command) was successively tested to estimate inter-
patients random variabilities (ETAs). The variance/covariance matrix was also tested for certain 
parameters only, if appropriate. Additive, proportional and combined (i.e., additive and proportional) 
error models were tested to describe the residual variability.  
The influence of gender, age and weight (the only covariates available) on the absorption and 
elimination parameters and on the apparent central volume of distribution was investigated. Covariates 
selected to enter the intermediate model simultaneously had to lead individually to a significant 
(p<0.01) decrease in the objective function from the covariate-free model. Finally, in a backward-
deletion strategy, each covariate was independently removed from the full model to confirm its 
relevance. If the increase in the objective function was not statistically significant (p<0.001), the 
relationship between this covariate and the respective pharmacokinetic parameter was not taken into 
account in the final model. The final model thus only included the significant covariates. At this stage, 
the clinical relevance of the covariate(s) was also appraised taking into account the reduction in IIV.   
Potential over-parameterization was tested taking into account the condition number (calculated as the 
square root of the ratio of the smallest to the largest eigenvalue) and the extreme eigenvalues. The 
stability and performance of the final population model were evaluated using the bootstrap approach. 
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Thousand bootstrap sets were drawn by resampling from the original dataset, each providing 
population PK parameter estimates. The mean, median and 95% confidence interval values estimated 
from the 1,000 bootstrap sets for each PK parameter were compared to those obtained with the 
original dataset. 
The adequacy of the final population model was evaluated by a Visual Predictive Check (VPC) 
performed using the „R for NONMEM‟ package [36]. A total of 1,000 datasets were simulated from the 
final model using the original data set. Plots of the median and 90% confidence interval of the 
simulated concentration versus time profiles were generated to check that the distribution of the 
observed concentration-time profiles was reasonably contained within this confidence interval. 
Because the MMF dose (in mg) was different in each patient, the predictions and the observations 
were dose normalized on the basis of the mean dose administered in the reference group (thereby the 
simulations were done using any dose). Moreover, the extent of shrinkage on each parameter (-
shrinkage) and on individual predictions (-shrinkage) was computed following Karlsson and Savic 
recommendations [37]. -shrinkage was calculated using the following formula : 1-SD(parameter)/ω, 
where SD(parameter) is the standard deviation of individual estimates of  for one parameter and ω the 
population estimated standard deviation of the corresponding random effect. Large values of 
shrinkage (higher than 20-30%) would generally be associated with poor individual estimates of that 
parameter. -shrinkage was calculated as 1-SD (IWRES), where IWRES are the individual weighted 
residuals, and will thus increase from zero toward one as data become less informative.  
 
2.3.2. NPAG analysis 
The nonparametric population analysis was performed using BigWinPops version 0.03 (R. Jeliffe, 
Laboratory of Applied Pharmacokinetics, USC Keck School of Medicine, Los Angeles, USA). One- and 
two-compartment models with first-order elimination and first-order absorption with or without a lag-
time were tested. The best model was selected on the basis of the log-likelihood of the results.  
The iterative two-stage Bayesian (IT2B) method was first used to obtain initial estimates of the PK 
parameter ranges. Then, nonparametric population analysis was performed using the NPAG program 
(29]. Combined with an interior point rather than an expectation-maximization algorithm, NPAG 
constitutes an improved version of the Nonparametric Expectation Maximization program, which 
computes the discrete joint probability density functions of the population pharmacokinetic parameters. 
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NPAG also computes a so-called  parameter, representing an overall measure of all the other 
sources of intra-individual variability besides the assay error, such as the errors in preparation and 
administration of the doses, errors in times of administration, misspecification of the pharmacokinetic 
model (residual error). Gamma is used as a multiplier of the assay error polynomial (Total error SD = 
gamma  Assay standard deviation). A value of gamma of 1.0 suggests that there is no other source 
of variability than the assay. A value of gamma >1.0 suggests that the environmental noise needs to 
be taken into account in the overall error by multiplying the value of gamma by the analytical error 
pattern.  
 
2.3.3. Evaluation of the performance of the population models 
The performance of NONMEM or NPAG population models was evaluated both in the index and in the 
test patient groups using Bayesian forecasting.  
Individual Bayesian estimates of individual pharmacokinetic parameters and AUCs were calculated for 
each patient included in the index group, using as priors the mean values and variability of the 
population pharmacokinetic parameters previously obtained with the best models retained with 
NONMEM and NPAG, respectively. Goodness of fit of the population models was evaluated by 
comparing Bayesian estimated and observed MPA plasma concentrations. 
Individual Bayesian estimates of MPA exposure and concentration values were also calculated for the 
36 patients included in the test group (56 concentration-time profiles) using the population 
characteristics of the index group and all the concentration-time points available. 
With NONMEM, the individual Bayesian estimates were obtained using the POSTHOC Bayesian 
option. With NPAG, Bayesian estimation of individual parameter values in independent patients was 
not available. Consequently, the final population model (i.e., mean parameter vector and full 
covariance matrix) was inserted into the PRIOR subroutine of the ADAPT II software package [38], to 
allow for maximum a posteriori Bayesian estimation. Two hypotheses related to the prior distribution 
model (normal or lognormal) were tested.  
 
2.4. Statistical analyses 
All statistical analyses were performed using the R software [39]. 
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Comparisons of patients‟ characteristics and MPA exposure indices between the index and test 
groups were performed using the Student t-test. 
Estimated and observed MPA concentrations and AUCs were compared using the mean relative error 
(MRE%) as a measure of bias, and root mean squared prediction error (RMSE) as a measure of 
precision. Statistical significance of the MRE was evaluated using the paired t-test.  
 
3. RESULTS 
3.1. Data description 
The characteristics of the patients included in the reference and test groups are summarized in Table 
1. No significant differences were observed between the two groups. Figure 1 shows the individual 
concentration-time curves observed during the four post-transplantation periods studied. For some 
profiles (less than 10 out of 129) a second concentration peak was observed at approximately 6h 
postdose, but most profiles exhibited a single concentration peak. The dose-normalized MPA AUC0-12 
[(AUC/dose)], calculated using the linear trapezoidal rule, was not significantly different between the 
two groups (p=0.126). A wide distribution of these dose-normalized MPA AUC0-12 was observed in 
each group at each period (Table 1), with some extremely high values, i.e. a very low apparent 
clearance. The Shapiro-Wilk normality test showed a significant deviation from the normal distribution 
of AUC/dose in both the reference (p<0.001) and the test (p=0.0018) groups, reflecting a non 
Gaussian distribution of the apparent clearance.  
 
3.2. Population modeling 
3.2.1. NONMEM analysis 
A two-compartment model with first-order, lagged time absorption and first-order elimination 
adequately described the concentration data. The model parameters were the absorption rate 
constant (ka), the apparent central volume of distribution (Vc/F), the rate constant from central to 
peripheral compartments (k12), the rate constant from peripheral to central compartments (k21), the 
elimination rate constant (ke) and the absorption lag-time. Introduction of IIV on ka, Vc/F, k12, ke and 
lag-time significantly improved the fit of the model. As the Box-cox and logit transformations failed to 
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improve model fitting and shrinkage, the IIV was modeled using an exponential error model. Inclusion 
of IOV on ka and Vc/F led to a significant decrease of the objective function value, but to negligible IIV 
values (1.04E-5% and 0.17%, respectively). Consequently, the final model included IOV on ka and 
Vc/F, IIV on k12, ke and lag-time, and a combined, additive and proportional, residual error. Finally, a 
simple diagonal matrix was selected. The population pharmacokinetic parameters (popPK) obtained 
are summarized in Table 2.  
Among the covariates investigated, only the post-transplantation period influenced ke with a 
statistically significant decrease of the objective function of 12 units (p<0.01). However, introduction of 
this covariate led to a high value of shrinkage estimates for ke (40%) and did not seem to significantly 
reduce ke unexplained inter-individual variability that still reached 14.3% (CI95%: 0 - 27.4%) versus 
19.9% (CI95%: 0 – 31.5%) with the covariate-free model. Therefore, the covariate-free model was 
finally retained. Diagnostic plots are shown in figure 2. The scatter plot of predicted (PRED) and 
individual model-predicted concentrations (IPRED) versus observed concentrations (DV) showed no 
major bias (Figure 2), while 91% of weighted residuals (WRES) were in the (-2 ; +2) range. 
Estimates of the shrinkage for ETAs of ka, k12, ke, Vc/F and lag-time were 0.096, 0.093, 0.352, 0.067 
and 0.199, respectively. The condition number was 14.7. The residual error was fairly high (38.7% and 
0.08 mg/L for the proportional and additive parts, respectively), but not shrunk (0.124). The mean 
parameter estimates obtained using the bootstrap procedure (1000 runs) were similar to those 
previously obtained with the original dataset (Table 2). 
Figure 3 shows the results of the VPC for the final model. Simulations were based on dose-normalized 
concentrations, using the mean MMF dose of 625 mg observed in the index group. The results are 
presented separately for profiles observed at early and stable post-transplant periods. The 
observations were within the 90% confidence interval but not distributed symmetrically relative to the 
median prediction. This shows the tendency of the model to underestimation.  
 
3.2.2. NPAG analysis 
The two-compartment model with first-order, time-lagged absorption and first-order elimination 
provided the best description of the data. The pharmacokinetic model included the same 6 
pharmacokinetic parameters as previously described for the parametric analysis: ka, Vc/F, k12, k21, 
ke and lag-time. 
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The initial IT2B analysis led to a value of γ of 0.89 suggesting that there was no other source of 
variability than the assay SD to consider in the model. Consequently, γ was set to 1, meaning that the 
total error (both assay and environmental) SD was equal to the error assay pattern SD. 
MPA pharmacokinetic parameter estimates in the index group are summarized in Table 3. Mean and 
median values of ka, lag-time and k21 were far apart, showing the heterogeneity and the asymmetry 
of their distribution. The results of the NPAG predictive performance evaluation are shown in Figure 4. 
The scatter plot of observed concentrations versus individual plasma concentrations predicted using 
the median parameter values of each patient‟s nonparametric Bayesian joint density (Bayesian 
posterior predicted levels) showed no major bias. 
3.2.3. Comparison between NONMEM and NPAG population models 
Except for Vc/F, the mean population pharmacokinetic parameter values obtained with NPAG were 
higher by at least 50% than with NONMEM. The two methods led to a similar high value of ka in an 
“outlier” patient, characterized by a very fast absorption of the drug. The range of the individual ke and 
lag-time values was much narrower with NONMEM (0.66 to 1.15 h
-1
 vs. 0.26 to 4.33 h
-1
 and 0.21 to 
0.33h vs. 0 to 1.85 h, respectively). Interestingly, the ke and lag-time skewness (2.03 and 1.70) and 
kurtosis (7.80 and 5.38) were not in favour of a normal distribution for these parameters.   
 
3.3. Evaluation of the predictive performance of the population models in the test group 
The predictive performance of the two final population models developed according to the NONMEM 
and NPAG methodologies is reported in Tables 2 and 3. The NPAG model resulted in more accurate 
and precise prediction of MPA AUC and concentrations than the NONMEM model, as shown by the 
lower and non significant bias and RMSE values. 
Using the nonparametric model, the best results were obtained with the lognormal prior distribution 
model option in ADAPT II. This model provided significantly lower mean AUC bias than the parametric 
model on M3 (0.79% vs -12.34%, p<0.001), M6 (7.50% vs -11.35%, p<0.05) and M9 (-0.25% vs -
12.39%, p<0.001) but not on W3 (3.56% vs 2.97%, NS).  
 
4. DISCUSSION 
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To the best of our knowledge, this study is the first to report population pharmacokinetic analysis of 
MPA using both parametric and nonparametric approaches (NONMEM and NPAG methods,  
respectively) in renal transplant children (from 1 to 18 years) and to show the superiority of the 
nonparametric modeling method. 
All the previous MPA population pharmacokinetic models developed both in adults and in children 
were based on parametric methods. Two population pharmacokinetic studies in pediatric renal 
transplant recipients were previously reported [24, 40]. Unlike the current study, Payen et al. [24], 
analyzed data collected in children and young adults, mainly in the stable post-transplantation period. 
Recently, Zhao et al. [40] reported a population pharmacokinetic model developed in children mainly 
focused on the period from before dosing to 3 h after (91% of the samples collected within this period). 
However, this sampling design did not allow describing the time-concentration curves beyond three 
hours post-dosing, i.e. when the MPA PK profiles are the most complex and probably the most 
variable. Therefore, different modeling strategies have been proposed in adults: (i) structural 
sophisticated models allowing to describe profile with two concentration peaks [41]; (ii) enterohepatic 
circulation [13,17] partly inhibited when cyclosporine is co-administered [42,43]; (ii) time-dependent 
clearance [15,9]. These approaches were tested herein and failed to improve the data fitting. In adult 
patients, the MPA pharmacokinetic modeling studies investigating the first weeks post-transplantation 
failed to estimate with precision the concentration profiles or yielded very high residual variability [15, 
26, 27].  
In the present study, the observed MPA concentration-time profiles mostly exhibited a single peak 
concentration and were best described by a two-compartment model with time-lagged first-order 
absorption. This is consistent with previous reports where MMF was co-administered with cyclosporine 
[15,17,24,25,27]. The analysis performed with NPAG led to higher values of MPA population PK 
parameters (except for Vc/F) and to a wider inter-individual variability than with NONMEM (especially 
for the elimination constant). The differences observed between the two approaches can be explained 
by the different calculation methods used by NONMEM and NPAG. Indeed, NONMEM is a parametric 
method in that it assumes a normal or log-normal distribution of the PK parameters and tends to put 
less weight on extreme values. This tendency can be highlighted by the -shrinkage expressing the 
shrinkage of the variance of empirical Bayes estimates distribution toward zero.  
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The high value of the calculated ke -shrinkage (35%), illustrates the trend to estimate individual ke 
values close to the population mean ( expressing the deviation of the individual parameter estimates 
from the typical parameter value in the population) which may be a problem since the estimates of this 
parameter are used for TDM. Indeed, with such high shrinkage values, posthoc s cannot be 
considered as informative about the true  distribution and the individual Bayesian estimates would be 
obtained with a large imprecision, which is hardly compatible with the development of Bayesian 
estimators for TDM. This result could be expected as the initial non-compartmental analysis showed a 
non-Gaussian distribution of the dose-normalized AUC in the reference group. 
One consequence of -shrinkage is that covariate relationships may be hidden, falsely induced, or the 
shape of the true relationship distorted [37]. This may partly contribute to the fact that, in the present 
study, no covariate was found significant. However, very few potential covariates were registered in 
the database used.  
The high value of shrinkage obtained for the elimination constant rate prompted us to ask ourselves 
about the relevance of standard parametric modeling (using fixed exponential transformation) and its 
ability to describe the shapes of the parameter distribution. Thus, two semi-parametric transformations 
(i.e. Box-cox and logit transformations) [30] were investigated but failed to improve the model fit.  
Finally, a nonparametric approach was used. In NPAG, no assumption is made about the shape of the 
parameters distribution which allows for many possible distributions and enables detection of the full 
diversity in the distribution of population parameters. This approach could reveal the true nature of the 
distribution of the elimination rate constant ke, allowing the description of subpopulations and the 
extreme values [44]. However, it is not possible (in the current state of the art) to determine the 
inaccuracy of estimates obtained using such a nonparametric approach. Consequently, shrinkage 
cannot be calculated. 
 
This study performed in children is the first focusing on a non normal distribution of MPA PK 
parameters. Such deviation from normality was not reported in adults. The high heterogeneity of the 
elimination constant values in children suggests the requirement of a wide range of doses to reach the 
target exposure. In clinical practice, this could result in a higher variability of administered doses in 
children than in adults. The mechanisms underlying this age-related difference in MMF dose 
requirements are largely unknown but could be related to developmental changes (also known as 
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ontogeny of drug disposition) of the UDP-glucuronosyltransferases, the enzyme family mainly 
responsible for MPA metabolism [40]. 
The results of the Bayesian estimation of MPA AUC and concentrations in the test patient group 
showed that the NPAG had a better predictive performance than the NONMEM model, as it yielded 
smaller and non-significant bias. The biased estimates obtained with the NONMEM model in the 
present case make it unsuitable for TDM. This result supports the assumption that NPAG would be 
preferable to NONMEM in case of multimodal or non-normal distribution of any one of the PK 
parameters in the model. However, the limit of the present results lies in the fact that Bayesian 
estimation of individual parameter values in the independent group of patients was not feasible in 
BigWinPops and was performed using ADAPT II, i.e. under the usual normality assumptions, which is 
not optimal in the case of non-normally distributed PK parameters.  
Another limitation is the lack of relevant covariates in our database. Indeed, while few demographic 
covariates, available for all patients, could be included in the population analysis, no major clinical 
variables, such as renal function or serum albumin which have been previously found related to MPA 
exposure in adults [13], were investigated due to many missing data. This is not a barrier to 
nonparametric analysis as, due to no assumption about the shape of the parameter distributions, 
unsuspected subpopulations of subjects can be detected without additional aid from covariates or 
other descriptors [32,44]. Finally, the  population model analysis reported in the present study dealt 
with pediatric renal transplant patients receiving a MMF/ciclosporine regimen and cannot be 
extrapolated to another immunosuppressive regimen like the MMF/tacrolimus association which is 
becoming more common in prevention of acute rejection. 
In conclusion, NPAG was a more adequate population pharmacokinetic method to describe the 
pharmacokinetics of MPA in pediatric renal transplant recipients. This finding could be linked to the 
studied database which included very few covariates able to explain the pharmacokinetic variability of 
MPA (such as serum albumin, blood hemoglobin and cyclosporine concentrations).  
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FIGURE LEGENDS 
Figure 1: Mycophenolic acid (MPA) concentration-time profiles of patients in the reference and test 
groups obtained at (a) week 3 (n=42), (b) month 3 (n=47), (c) month 6 (n=23) and (d) month 9 (n=17) 
post-transplant.  
Figure 2: Scatter plots of (A) observed concentrations (DV) versus population model-predicted 
concentrations (PRED), (B) observed concentrations (DV) versus individual model-predicted 
concentrations (IPRED), (C) weighted residuals (WRES) versus model-predicted concentrations 
(PRED) and (D) weighted residuals (WRES) versus time. 
Figure 3: Visual predictive check results of mycophenolic acid (MPA) for (a) early (W3) and (b) stable 
(M3 and M6) post-transplant periods. Symbols denote observation. Solid line and dashed lines 
represent the median and the 90% tolerance interval, respectively. Concentrations are corrected to a 
mycophenolate mofetil dose of 625 mg.  
Figure 4: Scatter plot of (A) observed and predicted plasma mycophenolic acid (MPA) concentrations 
based on the population median parameter values and (B) observed and predicted plasma MPA 
concentrations based on the median value of each subject‟s individual nonparametric Bayesian 
posterior parameter distributions obtained using NonParametric Adaptive Grid (NPAG).  
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Table 1. Demographic characteristics of the patients and mycophenolic acid (MPA) dose-normalized 
AUC0-12 (mg.h/mL)/mg at the different sampling periods. 
 
 
 Reference group (n=34) Test group (n=32) 
Age (years)
a
 11.2  3.2 8.9  4.9 (NS) 
Bodyweight (kg)
 a
 32.2  11.5 30.5  16.1 (NS) 
Sex ratio M/F
 a
 23/11 19/13 
Mycophenolate mofetil dose (mg)
 a
 625  178 569  213 (NS) 
MPA dose-normalized AUC0-12 (mg.h/mL)/mg
b
  
- All periods  106 (18 – 415) 91 (32 – 251) 
- Week 3 53 (18 – 176) 54 (37 – 122) 
- Month 3 104 (45 – 415) 91 ( 42 – 228) 
- Month 6 97 (35 – 183) 124 (78 – 251) 
- Month 9 -
c
 106 ( 32 – 217) 
a
data are given as meanSD 
b
data are given as median (range) 
c
 reference group did not include data on month 9 post-transplantation 
NS= no significant difference with respect to the reference group 
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Table 2. Mycophenolic acid (MPA) population pharmacokinetic parameters, inter-individual and inter-occasion variabilities, range of individual estimates 
obtained with the POSTHOC option, and results of the bootstrap internal validation procedure. Bias and precision of Bayesian estimates of MPA exposure in 
the test group (32 patients, n=56 concentration-time profiles) based on NONMEM population model. 
Parameter 
Final model 
original dataset 
Range of 
individual 
estimates 
 
Bootstrap
a
 
   
Bayesian forecasting  
 
 mean (SE)   mean  SE median 5
th
-95
th
 percentiles    
Fixed effect parameters       AUC0-12  
ka (h
-1
) 2.28 (0.51) 0.22-20.41  2.04  0.53 1.88 1.42-3.06  Bias, MRE % -9.53
b
 
Vc/F (L) 17.7 (1.84) 4.09-64.97  17.31  2.90 17.10 12.60-22.12  Precision, RMSE % 14.51 
K12 (h
-1
) 0.58 (0.10) 0.17-1.55  0.60  0.12 0.57 0.46-0.80  Range of relative error -24.13%; + 36.83% 
K21 (h
-1
) 0.007 (0.001) -  0.009  0.01 0.006 0-0.018    
ke (h
-1
) 0.78 (0.07) 0.66-1.15  0.85  0.14 0.83 0.65-1.10  Plasma concentrations  
Lag-time(h) 0.26 (0.01) 0.21-0.33  0.24  0.03 0.25 0.18-0.28  Bias, MRE % 13.67
b
 
Inter-individual variability       Precision, RMSE% 77 
ω(k12) (%) 62 (CI 95 11-87)   62  13 63 40-80    
ω(ke) (%) 20 (CI 95 0-31)   27  19 20 0-69    
ω(lag-time) (%) 15 (CI 95 0-23)   31  23 18 0-70    
Inter-occasion variability         
ω(ka) (%) 109 (CI 95 68-139)   99  17 100 67-125    
ω(Vc/F) (%) 53 (CI 39-63)   53  7 53 42-63    
Residual variability         
σ1 (%) 38.7   38  3 38 34-42    
σ2 (mg/L) 0.08   0.11  0.08 0.11 0-0.23    
ka, absorption constant; Vc/F, apparent central volume of distribution ; k12 and k21, inter-compartment transfer constants, ke, elimination rate constant, lag-time, absorption lag-
time. 
a
 Data from 1000 bootstrap analyses. 
b
 p<0.05 
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Table 3. Mycophenolic acid (MPA) population pharmacokinetic parameters obtained in NonParametric Adaptive Grid (NPAG). Bias and precision of Bayesian 
estimates of MPA exposure in the test group (32 patients, n=56 concentration-time profiles) based on NPAG population model. 
NPAG population model in reference group  Bayesian forecasting in test group 
Parameter Mean Median Inter-individual variability [Range]  using NPAG model as PRIORS in ADAPTII 
   (CV%)    Normal
a
 Lognormal
a
 
ka (h
-1
) 5.21 2.87 92.20 [0.10 – 20.10]  AUC0-12   
Vc/F (L) 16.11 12.13 74.80 [1.80 – 56.92]  Bias, MRE % 1.40 -1.68 
K12 (h
-1
) 1.30 1.05 82.16 [0.002 – 5.00]  Precision, RMSE % 12.10 6.87 
K21 (h
-1
) 0.69 0.03 207.83 [0.005 – 4.99]  Range of relative error -11.46%;+65.35% -11.22%;+26.29% 
ke (h
-1
) 1.16 1.05 56.40 [0.26 – 4.33]  Plasma concentrations   
Lag-time (h) 0.40 0.28 98.54 [0.0001 – 1.85]     Bias, MRE % 11.53 13.6 
         Precision, RMSE% 44.71 50.02 
ka, absorption constant; Vc/F, apparent central volume of distribution ; k12 and k21, inter-compartment transfer constants, ke, elimination rate constant, lag-time, 
absorption lag-time. 
a
 prior distribution model used in ADAPT II. 
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